| Document |
Document Title |
|
WO/2007/054100A2 |
The invention provides for a compound of formula I for use in medicine: (Formula I).
|
|
WO/2007/053869A2 |
The invention relates to compounds of general formula (1), in which R1, R2, R3 and R4 are defined as cited in the description and R5 is either the radical of a base of general formula (3), in which R8 and R9 independently of one another ...
|
|
WO/2007/056213A2 |
The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When ...
|
|
WO/2007/056191A2 |
The invention provides methods of removing contaminants from a mixture of a desired product and contaminants by pH adjustments and molecular weight cut-offs. The contaminants include phosphate groups, magnesium sulfate, sodium pyruvate a...
|
|
WO/2007/053702A2 |
This invention provides a process for making 3'-O- allyl-dGTP-PC-Biodopy-FL-51O, 3' -0-allyl-dATP-PC-ROX, 3'-O-allyl-dCTP-PC-Bodipy-650 and 3' -O-allyl-dUTP-PC- R6G, and related methods.
|
|
WO/2007/049736A1 |
This invention provides a process for producing a natural product having stable quality with high recovery. There is also provided a method for concentration-crystallizing a natural product, characterized by comprising continuously measu...
|
|
WO/2007/049294A1 |
A process for isolating ß-anomer enriched Gemcitabine hydrochloride by converting Gemcitabine base into Gemcitabine hydrochloride followed by its purification using solvents from the series of water soluble ethers like 1,4-dioxane or Mo...
|
|
WO/2007/047401A2 |
Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocar...
|
|
WO/2007/045998A2 |
The invention relates to non-natural bases and base pairs that expand the normal DNA-based encoding system. Compositions herein may comprise at least one non-natural base that may interact with another base via a Watson Crick-type hydrog...
|
|
WO/2007/038860A2 |
The present invention includes the utility of anti-viral and/or antibacterial effective amounts of 6-substituted nucleoside derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine monophosphate) in the treatment or prevention of...
|
|
WO/2007/038859A1 |
The present invention includes methods of treating or preventing malaria by administering an anti-malarial effective amount of 6-substituted uridine derivatives to a subject need thereof. The invention also includes new 6-substituted uri...
|
|
WO/2007/041342A2 |
Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, includi...
|
|
WO/2007/041637A2 |
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods ...
|
|
WO/2007/039413A2 |
The present invention relates to a one-step process for the selective O-acylation of the hydroxy groups of a nucleoside under basic conditions utilizing DMAP and a carboxylic acid anhydride in aqueous heterogenous solvent mixture.
|
|
WO/2007/041071A2 |
Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2'-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabi...
|
|
WO2007012494B1 |
The invention relates to stable nicotinamide adenine dinucleotide (NAD/NADH) derivatives or nicotinamide adenine dinucleotide phosphate (NADP/NADPH) derivatives of formula (I), enzyme complexes of said derivatives, and the use thereof in...
|
|
WO/2007/029364A1 |
It is intended to provide an MGB polyamide hybrid compound which has a function of recognizing a base sequence useful in gene therapy, is efficacious in synthesizing an oligomer and has a high stability. An MGB polyamide hybrid compound ...
|
|
WO/2007/029082A2 |
The present invention relates to an improved fermentation process for the preparation of ascomycin.
|
|
WO/2007/027564A2 |
Provided is a process for preparing gemcitabine or a salt thereof, which preferably includes removing at least a substantial portion of the α anomer of a N-1-protected-2'-deoxy-2',2'-difluoro-cytidine-3',5'-diester
from an anomeric mix...
|
|
WO/2007/020193A2 |
The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention fur...
|
|
WO/2007/018259A1 |
A method for purification of cytidinediphosphoric choline comprising the steps of contacting a cytidinediphosphoric choline solution having a pH of 0.5 to 5.0 (inclusive) and containing a nucleic acid analogue with a H-type strongly acid...
|
|
WO/2007/015257A2 |
The present invention provides a commercially viable process for preparing gemcitabine and its pharmaceutically acceptable acid addition salts thereof in high yield and purity using novel intermediates.
|
|
WO/2007/012177A1 |
Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound is a new therapeutic anti HIV option, in combination with another drug such as a NRTI or a protease inhibitor. It's heightened and sustained antiretroviral...
|
|
WO/2007/009757A1 |
The invention relates to novel adenosine receptor agonists of formula (I), methods for their manufacture and their use as medicaments.
|
|
WO/2007/010515A1 |
The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1 , R2, R...
|
|
WO/2007/009303A1 |
The present invention discloses a process for synthesizing Compound (I) of N4-acyl-5'-deoxy-5-fluorocytidine derivatives. The present invention utilizes Bis (trichloromethyl) carbobate as acylating agent for introducing protective lacton...
|
|
WO/2007/009147A2 |
The invention relates to homogemcitabines of general formula (2), with the meanings for the substituents as given in claim 1, method for production thereof, use for the production of the active agent gemcitabin and the use thereof for th...
|
|
WO/2007/004244A1 |
The invention concerns the production of salts or chelates of methyl donors, in particular S-adenosyl-L-methionine or SAMe and betaine or N1N1N- trimethylglycine, with phytic acid or with phosphorylate inositol, possibly partially salifi...
|
|
WO/2007/004230A2 |
The present invention relates to novel crystalline alkali metal and alkaline earth metal salts of 2',3'-dideoxy-2',3'-didehydroinosine. The present invention also provides a novel process for preparation of didanosine in high yield and p...
|
|
WO/2006/138396A2 |
A process for providing regiospecific and highly stereoselective synthesis of 9-β anomeric purine nucleoside analogs is described. The introduction of the sugar moiety on to 6-(azolyl)-substituted purine bases is performed so that highl...
|
|
WO/2006/137953A1 |
Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are 5-phosphono-pent-2-en-l-yl...
|
|
WO/2006/133611A1 |
The present invention discloses N2-quinolyl or isoquinolyl substituted purine derivatives, and pharmaceutical compositions containing them. The compounds of the invention have the characteristic of lower toxicity, broad anticancer spectr...
|
|
WO/2006/132808A1 |
A process of preparing an alpha-anomer enriched 2- deoxy-2 , 2-dif luoro-D-ribofunanosyl sulfonate, which is useful as an intermediate in the preparation of a beta nucleoside, such as gemcitabine, an anti-tumor agent. A beta-2-deoxy-2, 2...
|
|
WO/2006/133092A1 |
The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are inde...
|
|
WO/2006/130217A2 |
Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are obtained by attaching the ...
|
|
WO/2006/128328A1 |
The invention provides a process for preparing didanosine. The process comprises removing the protecting group in position 5’ of compound II by hydrolysis under the basic condition, and synchronously enolizating of the carbonyl group o...
|
|
WO/2006/127009A1 |
The present invention provides the combination of the O-2 diphenylcarbamoyl ('DPC') and N-6 dimethylaminomethylidene ('DMF') protecting groups for isoguanosine nucleosides that can be utilized in oligonucleotide synthesis.
|
|
WO/2006/127906A1 |
Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhib...
|
|
WO/2006/125211A1 |
Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula (I): which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and m...
|
|
WO/2006/125190A1 |
Disclosed are novel compounds that are partial and foil A1 adenosine receptor agonists having the structure of Formula (I) : which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and ...
|
|
WO/2006/121820A1 |
The invention concerns 2'-methyl ribonucleotide phosphoramidates which are neutral prodrugs which are converted in vivo to 2'- methyl ribonucleotide triphosphates. These compounds are useful in the treatment of viral infection. Of partic...
|
|
WO/2006/122207A1 |
Compounds of formula I, are provided, which are useful as inhibitors of hepatitis C virus.
|
|
WO/2006/121468A1 |
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
|
|
WO/2006/117161A2 |
The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.
|
|
WO/2006/119347A1 |
This invention relates to a process for stereoselectively preparing a nucleoside of the following formula: wherein R3, R4, and B are defined herein. The process includes reacting a furanose compound with a nucleobase in the presence of a...
|
|
WO/2006/114336A1 |
The invention relates to new side chain-fluorinated 3'-deoxythymidine derivatives of the general formula (I) or physiological acceptable esters thereof, wherein R = CH218F; CH18F2; CH2F or CHF2 and Y = H, N3 or Hal. The invention also re...
|
|
WO/2006/115137A1 |
Disclosed is a 2-aminobenzimidazole derivative which is effective for a disease cause by abnormal serum uric acid level. A 2-aminobenzimidazole derivative represented by the general formula (I) or a prodrug thereof or a pharmacologically...
|
|
WO/2006/116557A1 |
Disclosed are compounds of formula I1 compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. HN' 'I f 1 CH, W1O X
|
|
WO/2006/116512A1 |
The present invention provides methods of utilizing a nucleoside derivative having the chemical formula of Formula (I) to downregulate expression of an anti-apoptotic protein such as survivin in a cell, induce apoptosis in a cell, inhibi...
|
|
WO/2006/111058A1 |
The present invention discloses a compound of formula (I), and/or stereoisomers and/or hydrates and/or solvates thereof. Wherein: R1 is saturated or unsaturated, straight-chain or branched hydrocarbyl, substituted hydrocarbyl. The presen...
|
